Get all your news in one place.
100’s of premium titles.
One app.
Start reading
Benzinga
Benzinga
Technology
Vandana Singh

Aura Biosciences' Belzupacap Sarotalocan At Par With Plaque Radiotherapy In Eye Cancer

  • Aura Biosciences Inc (NASDAQ:AURAreported data from a retrospective analysis that assessed the visual acuity after plaque radiotherapy treatment compared with prospective data in early-stage choroidal melanoma patients treated with belzupacap sarotalocan by intravitreal administration in the Phase 1b/2 trial.
  • The vision results of patients with early-stage choroidal melanoma treated with radiotherapy showed the long-term, progressive, and irreversible loss of visual acuity in patients with tumors near the fovea.
  • The loss of vision in radiotherapy patients was ≥3 lines in most patients as early as 2 years and ≥6 lines as early as 3 years.
  • The findings of this retrospective study were consistent with published clinical data supporting the irreversible loss of visual acuity after treatment with radiotherapy.
  • Due to the retrospective nature of this analysis, it is hypothesis-generating. Hence no formal conclusions can be drawn.
  • Aura has also initiated a prospective matched case-control study to further evaluate the long-term visual acuity of belzupacap sarotalocan from the Phase 2 trial AU-011-202 using suprachoroidal administration versus radiotherapy.
  • Price Action: AURA shares are up 10.11% at $14.49 during the premarket session on the last check Thursday.
Sign up to read this article
Read news from 100’s of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member? Sign in here
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.